Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2020 Jun 23;64(7):e01014-20. doi: 10.1128/AAC.01014-20

Erratum for Reitzel et al., “Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms”

Ruth A Reitzel a,✉, Joel Rosenblatt a, Bahgat Z Gerges a, Nylev Vargas-Cruz a, Issam I Raad a
PMCID: PMC7318049  PMID: 32576597

ERRATUM

Volume 64, no. 4, e02146-19, 2020, https://doi.org/10.1128/AAC.02146-19. The following paragraph should be included at the end of the article text:

ACKNOWLEDGMENTS

I. I. Raad and J. Rosenblatt are inventors of the minocycline-EDTA-ethanol catheter lock solution technology which is owned by the University of Texas MD Anderson Cancer Center (UTMDACC) and has been licensed to Novel Anti-Infective Technologies, LLC, in which Drs. Raad and Rosenblatt and UTMDAAC are shareholders, and has been sublicensed to Citius Pharmaceuticals Inc., for whom Dr. Raad is a scientific advisor and shareholder and Dr. Rosenblatt is a consultant and shareholder.

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES